- Home
- SRRK vs LNTH Comparison
SRRK vs LNTH Comparison
Compare SRRK & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRRK | LNTH |
|---|---|---|
| Founded | 2012 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.4B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SRRK | LNTH |
|---|---|---|
| Price | $47.62 | $64.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $51.20 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 1.0M | 728.8K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | N/A | ★ $1,525,933,000.00 |
| Revenue This Year | N/A | $0.01 |
| Revenue Next Year | $20,029.43 | $0.26 |
| P/E Ratio | ★ N/A | $27.10 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $22.71 | $47.25 |
| 52 Week High | $49.82 | $111.29 |
Technical Indicators
Market Signals| Indicator | SRRK | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 43.81 |
| Support Level | $44.10 | $64.25 |
| Resistance Level | $49.82 | $68.70 |
| Average True Range (ATR) | 2.35 | 2.15 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 45.47 | 26.76 |
Price Performance
Historical ComparisonAbout SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.